The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: A prospective open-label study

8Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The efficacy of antipsychotics can be evaluated using the dimensional models of schizophrenic symptoms. The D2/D3-selective antagonist amisulpride has shown similar efficacy and tolerability to other atypical antipsychotics. The aim of the present study was to determine the efficacy of amisulpride on the dimensional model of schizophrenic symptoms and tolerability in latin schizophrenic patients. Method: Eighty schizophrenic patients were enrolled and 70 completed a prospective open-label 3-month study with amisulpride. The schizophrenic symptoms, psychosocial functioning and sideeffects were evaluated with standardized scales. Results: The patients showed significant improvement in the five dimensions evaluated. Amisulpride (median final dose 357.1 mg/d) was well-tolerated without treatment-emergent extrapyramidal side-effects. Conclusion: Amisulpride showed efficacy on different psychopathological dimensions and was well tolerated, leading to consider this drug a first line choice for the treatment of schizophrenia. © 2005 Herrera-Estrella et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Herrera-Estrella, M., Apiquian, R., Fresan, A., & Sanchez-Torres, I. (2005). The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: A prospective open-label study. BMC Psychiatry, 5. https://doi.org/10.1186/1471-244X-5-22

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free